Holen Sie sich die Stockscreener-App
4.04
4.49%
-0.19
Handel nachbörslich:
4.01
-0.03
-0.74%
Schlusskurs vom Vortag:
$4.23
Offen:
$4.22
24-Stunden-Volumen:
356.15K
Relative Volume:
0.48
Marktkapitalisierung:
$400.55M
Einnahmen:
$9.01M
Nettoeinkommen (Verlust:
$-99.72M
KGV:
-0.8902
EPS:
-4.5381
Netto-Cashflow:
$-92.85M
1W Leistung:
+0.00%
1M Leistung:
+2.80%
6M Leistung:
+17.44%
1J Leistung:
-1.94%
1-Tages-Spanne:
$4.00
$4.23
1-Wochen-Bereich:
$3.94
$4.39
52-Wochen-Spanne:
$2.80
$4.83
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Firmenname
X 4 Pharmaceuticals Inc
Sektor
Branche
Telefon
857-529-8300
Adresse
61 NORTH BEACON STREET, BOSTON, MA
Compare XFOR vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
4.04 | 399.56M | 9.01M | -99.72M | -92.85M | -4.5381 |
VRTX
Vertex Pharmaceuticals Inc
|
541.69 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
794.19 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,023.21 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.99 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
207.88 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-09 | Eingeleitet | Guggenheim | Buy |
| 2025-12-05 | Fortgesetzt | Stifel | Buy |
| 2023-12-12 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2023-08-30 | Fortgesetzt | B. Riley Securities | Buy |
| 2022-12-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-12 | Eingeleitet | Piper Sandler | Overweight |
| 2019-12-23 | Eingeleitet | Oppenheimer | Outperform |
| 2019-12-18 | Eingeleitet | ROTH Capital | Buy |
| 2019-12-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-12-05 | Eingeleitet | B. Riley FBR | Buy |
| 2019-06-07 | Eingeleitet | Stifel | Buy |
| 2019-06-05 | Eingeleitet | Cowen | Outperform |
Alle ansehen
X 4 Pharmaceuticals Inc Aktie (XFOR) Neueste Nachrichten
Deep Track Capital, LP Boosts X4 Pharmaceuticals (XFOR) Stake by 26.84% - GuruFocus
Is OPK Worth Buying as Valuation Meets Improving Business Trends? - TradingView
X4 (XFOR) Financial Update: Profit Per Share Clears Its Benchmark in Latest Trading; Closing Reaction - vinanet.vn
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
X4 Pharmaceuticals: Making Progress, But The Market Is Ahead Of The Trial (Rating Downgrade) - Seeking Alpha
Layoff Tracker: Kolon TissueGene cuts 37 US staffers after Phase 3 fail - BioSpace
X4 (XFOR) Share-Price Review: Closes 2.09% Lower at $4.21 in the Current Update; Price-Level Context: the Near-Term Reference Band Stretches From $4.00 to $4.42 in Latest TradingChandelier Stop - vinanet.vn
Fierce Biotech Layoff Tracker 2026: Kolon cuts workforce after ph. 3 fail; Sanofi sheds 229 staffers - Fierce Biotech
C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Study Explores Industry Growth Toward $2.75 Billion - openPR.com
Perceptive Advisors (XFOR) reports 8.1% beneficial stake in X4 Pharmaceuticals - Stock Titan
Supernus Pharmaceuticals (SUPN) CMO Rubin exercises PSUs and withholds shares for tax - Stock Titan
Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk? - TradingView
4 Best Pharmaceutical Stocks for 2026 and How to Invest - The Motley Fool
Deep Track Capital (XFOR) discloses 8.33% X4 Pharmaceuticals stake with capped warrants - Stock Titan
X4 Pharmaceuticals President John Volpone Sells 24,576 Shares to Settle Tax on RSU Award - Kalkine Media
John Volpone Sells 24,576 Shares of X4 Pharmaceuticals (NASDAQ:XFOR) Stock - MarketBeat
X4 Pharmaceuticals (NASDAQ:XFOR) Chairman Sells $210,615.84 in Stock - MarketBeat
X4 Pharma chairman Craig R. sells $210,829 in shares - Investing.com
X4 Pharma chairman Craig R. sells $210,829 in shares By Investing.com - Investing.com India
X4 Pharmaceuticals Executive Chairman Adam R. Craig Sells 47,436 Shares to Cover RSU Tax Liability - Kalkine Media
X4 Pharmaceuticals, Inc SEC Filing (Aug 13, 2026) - Stock Titan
Industry Analysts Just Made A Dazzling Upgrade To Their X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Revenue Forecasts - simplywall.st
Earnings Update: X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Just Reported And Analysts Are Boosting Their Estimates - webull.com
X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's Why - Yahoo Finance
XFOR Q3 EPS Estimate Lifted by Brookline Capital Markets - marketbeat.com
Equities Analysts Issue Forecasts for XFOR FY2029 Earnings - MarketBeat
X4 Pharmaceuticals Inc (XFOR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
X4 Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
X4 Pharmaceuticals (XFOR) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
X4 Pharmaceuticals: Q2 Earnings Snapshot - Yahoo Finance
X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Yahoo Finance
X4 Pharmaceuticals (NASDAQ: XFOR) wins EU nod, posts $16.2M Q2 loss - Stock Titan
XFOR Q2'26 Earnings: EPS estimate is (0.18) USD - tradingview.com
Form 4 Rocket Pharmaceuticals Inc For: 6 August By Investing.com - Investing.com Nigeria
X4 Pharmaceuticals Inc expected to post a loss of 18 cents a shareEarnings Preview - TradingView
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Perceptive Advisors LLC Increases Stake in X4 Pharmaceuticals, Inc. $XFOR - MarketBeat
Form 4 Supernus Pharmaceuticals Inc For: 31 July By Investing.com - Investing.com UK
XFOR|X4 Pharmaceuticals Inc|Price:3.980|Chg%:-0.020 - TradingKey
BlackRock (NYSE: BLK) discloses 5.9% ownership of X4 Pharmaceuticals (XFOR) stock - Stock Titan
Form 4 Processa Pharmaceuticals Inc For: 28 July By Investing.com - Investing.com UK
Form 4 Olema Pharmaceuticals Inc For: 27 July By Investing.com - Investing.com South Africa
X4 Pharmaceuticals Inc (XFOR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
X4 Pharmaceuticals Inc (XFOR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
X4 Pharmaceuticals Inc (XFOR) Valuation: PE, PB & Fair Value Analysis - TradingKey
X4 Pharmaceuticals Inc (XFOR) Cash Flow - TradingKey
XFOR|X4 Pharmaceuticals Inc|Price:3.930|Chg%:+0.080 - TradingKey
X4 Pharmaceuticals Inc (XFOR) Balance Sheet - TradingKey
X4 Pharmaceuticals Market Sentiment - Benzinga España
X4 Pharmaceuticals Inc (XFOR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
X4 Pharmaceuticals, Inc. Revenue Breakdown – FWB:48Q0 - TradingView
Finanzdaten der X 4 Pharmaceuticals Inc-Aktie (XFOR)
Umsatz
Nettogewinn
Free Cashflow
ENV
X 4 Pharmaceuticals Inc-Aktie (XFOR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Craig Adam R | Executive Chairman |
Aug 12 '26 |
Sale |
4.44 |
47,436 |
210,829 |
328,651 |
8.37%
0.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):